Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS >= 3) recurrent ovarian cancer (ROC) receiving >= 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS). Roncolato, F. T., O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P. P., Oza, A. M., Avall-Lundqvist, E., Berek, J. S., Sjoquist, K., Gillies, K., Butow, P., Stockler, M. R., King, M., Friedlander, M. AMER SOC CLINICAL ONCOLOGY. 2015
View details for Web of Science ID 000358036901228